Cargando…

Satralizumab for neuromyelitis optica spectrum disorder

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: NPS MedicineWise 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882450/
https://www.ncbi.nlm.nih.gov/pubmed/35233140
http://dx.doi.org/10.18773/austprescr.2021.065
_version_ 1784659703162208256
collection PubMed
description
format Online
Article
Text
id pubmed-8882450
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher NPS MedicineWise
record_format MEDLINE/PubMed
spelling pubmed-88824502022-02-28 Satralizumab for neuromyelitis optica spectrum disorder Aust Prescr New Drugs NPS MedicineWise 2021-12-10 2022-02 /pmc/articles/PMC8882450/ /pubmed/35233140 http://dx.doi.org/10.18773/austprescr.2021.065 Text en (c) NPS MedicineWise https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle New Drugs
Satralizumab for neuromyelitis optica spectrum disorder
title Satralizumab for neuromyelitis optica spectrum disorder
title_full Satralizumab for neuromyelitis optica spectrum disorder
title_fullStr Satralizumab for neuromyelitis optica spectrum disorder
title_full_unstemmed Satralizumab for neuromyelitis optica spectrum disorder
title_short Satralizumab for neuromyelitis optica spectrum disorder
title_sort satralizumab for neuromyelitis optica spectrum disorder
topic New Drugs
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882450/
https://www.ncbi.nlm.nih.gov/pubmed/35233140
http://dx.doi.org/10.18773/austprescr.2021.065